|
1 Burmester G.R., et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases Ann Rheum Dis. 2009;68:1863–1869. | ||
|
2 Papp K.A., et al. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. NEJM. 2017. | ||
|
3 Duvallet E, Sererano L, Assier E, et. al. Interleukin-23: a key cytokine in inflammatory diseases. Ann Med. 2011 Nov;43(7):503-11. | ||
|
4 Pipeline – Our Science | AbbVie. Available at: https://www.abbvie.com/our-science/pipeline.html. Accessed on February 9, 2018. | ||
|
5 A Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT03105128. Accessed on February 2, 2018. | ||
|
6 BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis. ClinicalTrials.gov. | ||
|
Available at: https://clinicaltrials.gov/ct2/show/NCT02719171. Accessed on February 2, 2018. | ||
|
7 A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065. ClinicalTrials.gov. 2018. Available at: https://www.clinicaltrials.gov/ct2/show/NCT03398135. Accessed on February 2, 2018. | ||
|
8 A Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy. ClinicalTrials.gov. 2018. Available at: https://www.clinicaltrials.gov/ct2/show/NCT03398148. Accessed on February 2, 2018. | ||
|
9 Gordon K, et al. Efficacy and Safety of Risankizumab: Results from Two Double-Blind, Placebo- and Ustekinumab-Controlled, Phase 3 Trials in Moderate-to-Severe Plaque Psoriasis. American Academy of Dermatology. February 2018. | ||
|
10 Voss, J, et al; Pharmacodynamics Of a Novel Jak1 Selective Inhibitor In Rat Arthritis and Anemia Models and In Healthy Human Subjects. [abstract]. Arthritis Rheum 2013;65 Suppl 10 :2374. DOI: 10.1002/art.2013.65.issue-s10 | ||
|
11 Pipeline – Our Science | AbbVie. Available at: https://www.abbvie.com/our-science/pipeline.html. Accessed on February 9, 2018. | ||
|
12 A Study Comparing ABT-494 to Placebo in Subjects With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone (SELECT-NEXT). ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT02675426. Accessed on February 2, 2018. | ||
|
13 A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (SELECT - PsA 1). ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT03104400. Accessed on February 2, 2018. | ||
|
14 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy. ClinicalTrials.gov Available at: https://clinicaltrials.gov/ct2/show/NCT02365649. Accessed on February 2, 2018. | ||
|
15 A Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects With Active Ankylosing Spondylitis (SELECT Axis 1). Available at: https://clinicaltrials.gov/ct2/show/study/NCT03178487. Accessed on February 2, 2018. | ||
|
16 Phase 2b AD Dose Ranging Study (40wk) N=160. ClinicalTrials.gov. Clinicaltrialsgov. Available at: https://clinicaltrials.gov/ct2/show/NCT02925117. Accessed on February 2, 2018. | ||
|
17 A Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT02819635. Accessed on February 2, 2018. | ||
|
18 AbbVie's (ABBV) CEO Richard Gonzalez on Q4 2017 Results - Earnings Call Transcript. Available at: https://seekingalpha.com/article/4140615-abbvies-abbv-ceo-richard-gonzalez-q4-2017-results-earnings-call-transcript. Accessed on February 6, 2018 | ||
|
19 HUMIRA Injection [package insert]. North Chicago, IL: AbbVie Inc. | ||
